Evidence map›Paper›PMID 37129296›Full record

ArticleThe British journal of radiology2023

Novel radiomic features versus deep learning: differentiating brain metastases from pathological lung cancer types in small datasets.

Gökalp Tulum

Abstract read
In one paragraph

Article in The British journal of radiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Gökalp TulumDepartment of Mechatronics Engineering, Engineering and Architecture Faculty, Nisantasi University, Istanbul, Turkey.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveAccurate diagnosis and early treatment are crucial for survival in patients with brain metastases. This study aims to expand the capability of radiomics-based classification algorithms with novel features and compare results with deep learning-based algorithms to differentiate the subtypes of lung cancer from MRI of metastatic lesions in the brain.

methodsThis study includes 75 small cell lung carcinoma, 72 squamous cell carcinoma, and 75 adenocarcinoma segments. For the radiomics-based algorithm, novel features from the original Laplacian of Gaussian filtered and two-dimensional wavelet transformed images were extracted, and a new three-stage feature selection algorithm was proposed for feature selection. Two classification methods were applied to images to identify the subtypes of lung cancer. Additionally, EfficientNet and ResNet with transfer learning were used as classifiers to compare the results of the proposed algorithm.

resultsThe sensitivity and specificity values of the radiomics-based classifier are 94.44 and 95.33%, and for the second classifier are 87.67% and 92.62%, respectively. Besides, a one

conclusionThe results suggest that the proposed radiomics-based algorithm is a helpful diagnostic assistant to improve decision-making for treating patients with brain metastases in small datasets. ADVANCES IN KNOWLEDGE: Firstly, the proposed method of this study extracts novel features from transformations of the original images, such as wavelet and Laplacian of Gaussian filter for the first time in literature. Secondly, this is the first study that investigates the classification performance of the shallow and deep learning approaches to identify subtypes of lung cancer.

Indexed as

AdenocarcinomaBrain NeoplasmsDeep LearningLung NeoplasmsSmall Cell Lung CarcinomaHumans

Identifiers

PMID37129296
PMCPMC10230391

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.